| __timestamp | Bristol-Myers Squibb Company | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3932000000 | 94103000 |
| Thursday, January 1, 2015 | 3909000000 | 146194000 |
| Friday, January 1, 2016 | 4946000000 | 130000 |
| Sunday, January 1, 2017 | 6066000000 | 7353000 |
| Monday, January 1, 2018 | 6547000000 | 34193000 |
| Tuesday, January 1, 2019 | 8078000000 | 56586000 |
| Wednesday, January 1, 2020 | 11773000000 | 63382000 |
| Friday, January 1, 2021 | 9940000000 | 97049000 |
| Saturday, January 1, 2022 | 10137000000 | 139989000 |
| Sunday, January 1, 2023 | 10693000000 | 150343000 |
| Monday, January 1, 2024 | 11949000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. From 2014 to 2023, Bristol-Myers Squibb Company (BMY) and Sarepta Therapeutics, Inc. (SRPT) have shown distinct trajectories in their cost of revenue. Bristol-Myers Squibb, a giant in the sector, has seen its cost of revenue grow by approximately 172%, peaking at over $10 billion in 2023. This reflects its expansive operations and robust product pipeline.
Conversely, Sarepta Therapeutics, a smaller player, has experienced a more modest increase of around 60% in the same period, reaching $150 million in 2023. This growth underscores its strategic focus on niche markets, particularly in genetic medicine. The stark contrast between these two companies highlights the diverse strategies within the pharmaceutical industry, where scale and specialization play pivotal roles in shaping financial outcomes.
AbbVie Inc. vs Bristol-Myers Squibb Company: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Bristol-Myers Squibb Company
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Incyte Corporation
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Pharming Group N.V.
Cost Insights: Breaking Down Bristol-Myers Squibb Company and Celldex Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for GSK plc and Sarepta Therapeutics, Inc.
Cost of Revenue Comparison: Viatris Inc. vs Sarepta Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Sarepta Therapeutics, Inc. vs Exelixis, Inc.
Cost of Revenue Trends: Sarepta Therapeutics, Inc. vs Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and ADMA Biologics, Inc.'s Expenses
Cost of Revenue Comparison: Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
Cost of Revenue Comparison: Sarepta Therapeutics, Inc. vs HUTCHMED (China) Limited